Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2017—Streck and GenomePrecision Technology, an integrated molecular diagnostics distributor in China, have signed a distribution agreement for Streck’s cell stabilization, molecular, urinalysis, and flow cytometry products.
May 2017—Accelerate Diagnostics announced that the FDA has granted the de novo request to market the Accelerate Pheno system and Accelerate PhenoTest BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples.
May 2017—Inova Diagnostics announced that the FDA has granted 510(k) clearance for its Nova Lite DAPI ANCA (ethanol) and Nova Lite DAPI ANCA (formalin) kits for use with Nova View, a digital IFA microscope. Nova Lite DAPI ANCA kits detect anti-neutrophil cytoplasmic antibodies on an automated digital IFA microscope.
May 2017—Randox has launched Acusera 24.7 Live Online 2.0, which is faster than the previous version, has a simplified user interface, and an enhanced user experience. The biggest update to version 2, according to a company statement, is the ability to review peer data in real time, which enhances troubleshooting capabilities and allows labs to identify trends.
May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.
May 2017—EntroGen has launched two sample quality assessment products to determine the quantity and quality of DNA samples prior to running downstream qPCR and NGS experiments. The DNA Fragmentation Quantification Assay and Library Quantification Kit for Illumina save samples, time, and reagents by implementing quality control steps before preparing libraries, loading a flow cell for sequencing, and setting up a qPCR or NGS assay. Both assays rely on real-time PCR technology and require a real-time PCR instrument capable of detecting FAM and VIC.
May 2017—Asuragen entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics. Asuragen will leverage its AmplideX PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument.
May 2017—Nova Biomedical received the CE mark for its Allegro, a capillary blood analyzer for point-of-care testing in primary care settings. Allegro and its StatStrip A companion meter provide 14 clinically important tests to monitor glycemic control, assess cardiac risk with a full lipids panel, and assess kidney function. Results are ready during the patient visit.
April 2017—Proscia, a data solutions provider for digital pathology founded in 2014 by a team from Johns Hopkins, the Moffitt Cancer Center, and the University of Pittsburgh, and Asan Medical Center, a South Korean clinical and biomedical research institute, announced a partnership focused on developing tools that enable predictive medicine in the fight against cancer.
April 2017—ViroStat has introduced three Monotope monoclonal antibodies that are specific to Chlamydia pneumonia and do not cross-react with the related Chlamydia trachomatis and Chlamydia psittaci. They function in ELISA and IFA and are candidates for rapid test applications.
